An investigational therapy could improve cognition, function and brain atrophy measures in Alzheimer’s patients, data shows. 

Valiltramiprosate, which received Fast Track designation from the US Food and Drug Administration (FDA) in 2017, is an investigational oral agent being evaluated as a potential first-in-class, disease-modifying treatment for Alzheimer’s disease (AD).  

Results from Phase II and Phase III clinical studies offer evidence supporting the biological activity of valiltramiprosate, its novel mechanism of action, and effects in therapeutic studies. 

Valiltramiprosate, developed by biopharmaceutical company Alzheon, is designed to inhibit the formation of neurotoxic soluble beta amyloid oligomers that contribute to cognitive decline in individuals with AD.  

The treatment employs an enveloping molecular mechanism of action intended to prevent the aggregation of soluble amyloid oligomers in the human brain, which are associated with the onset and progression of cognitive impairment in AD patients. 

Biomarker analyses of Phase II and III studies examining the effects of valiltramiprosate revealed consistent and early decreases in plasma p-tau217, which is a biomarker linked to beta amyloid and early tau pathology.  

In the Phase III trial, participants who received valiltramiprosate for 78 weeks showed reductions in p-tau217 starting at 26 weeks, which continued throughout the treatment period. There were even greater benefits seen in patients at the Mild Cognitive Impairment (MCI) stage. 

“Our new biomarker results offer robust biological validation for valiltramiprosate’s upstream molecular mechanism, designed to inhibit formation of neurotoxic soluble amyloid oligomers, which are considered pivotal drivers of Alzheimer’s disease pathology,” said John Hey, Chief Scientific Officer of Alzheon.  

“The consistent demonstration of Alzheimer’s positivity, early and sustained reductions in p-tau217, and strong correlations with cognitive, functional, and imaging outcomes highlight the importance of p-tau217 as a marker for disease progression and treatment efficacy, particularly in patients at earlier stages of Alzheimer’s disease.”